

Curriculum Vitae – Dagmar Stoiber-Sakaguchi

Name and Address Dagmar Stoiber-Sakaguchi, MMag.Dr.
Ludwig Boltzmann Institute for Cancer Research (LBI-CR)
Währingerstr. 13a, A-1090 Vienna, Austria
Phone: (+43-1)-40160 71240 Fax: (+43-1)-40160 931300
Email E-mail: dagmar.stoiber@lbicr.lbg.ac.at
Citizenship Austrian

University Studies

2000 PhD thesis “Molecular mechanisms involved in the process of macrophage activation induced by interferon- γ and infectious microorganisms or their products” with Prof. Thomas Decker
1997-2000 Department of Microbiology and Genetics, University of Vienna, Austria, PhD student
1995-1996 Diploma thesis: “Studies on tyrosine phosphorylation and transactivation ability of STAT5 in cells of the macrophage lineage” with Prof. Thomas Decker
1991-1996 Study of Microbiology, University of Vienna, Vienna, Austria

Research and Professional Experience

2005 – present Group leader at the Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
2002 - present University assistant at the Institute of Pharmacology, Medical University of Vienna, Austria
2000-2001 Postdoc with Prof. Tadatsugu Taniguchi at the Department of Immunology, University of Tokyo, Japan
2000 Postdoc, at the Institute of Microbiology and Genetics, University of Vienna, with Prof. Thomas Decker

Funded Grants	n=03	
Scientific Awards	n=02	
Original Articles	n=23	(including Reviews and Book chapters)
Total Impact Factor	231.7	
H-Factor	11	
Citation Index Total	1267	

Honors and Awards

Heribert Konzett Prize (2010)
Sanofi Aventis Award (2005)

Number of Peer-Reviewed Publications:

21 original articles, 1 commentary, 1 review

Peer-Reviewed Publications

Original Articles (OA-1 to OA-21)

- OA-21** Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Müller M, Sexl V & **Stoiber D**. Conditional IFNAR1 ablation reveals distinct requirements of type IFN signaling for NK cell maturation and tumor surveillance. *Onc Immunology*. 2012;1:1027-37. **[Impact Factor pending]**
- OA-20** Musteanu M, Blaas L, Zenz R, Svinka J, Hoffmann T, Grabner B, Schramek D, Kantner HP, Müller M, Kolbe T, Rüllicke T, Moriggl R, Kenner L, **Stoiber D**, Penninger JM, Popper H, Casanova E, Eferl R. A mouse model to identify cooperating signaling pathways in cancer. *Nat Methods*. 2012;9:897-900. **[Impact Factor: 19.3]**
- OA-19** Kernbauer E, Maier V, **Stoiber D**, Strobl B, Schneckenleithner C, Sexl V, Reichart U, Reizis B, Kalinke U, Jamieson A, Müller M & Decker T. Conditional Stat1 ablation reveals the importance of interferon signaling for immunity to Listeria monocytogenes infection. *PLoS Pathogens*. 2012;8: e1002763. **[Impact Factor: 9.2]**
- OA-18** Rohr-Udilova N, Sieghart W, Eferl R, **Stoiber D**, Björkhem-Bergman L, Eriksson LC, Stolze K, Hayden H, Keppler B, Sagmeister S, Grasl-Kraupp B, Schulte-Hermann R & Peck-Radosavljevic M. Antagonistic effects of selenium and lipid peroxide on growth control in early hepatocellular carcinoma. *Hepatology*. 2012;55:1112-21. **[Impact Factor: 11.7]**
- OA-17** Fuka G, Kantner HP, Grausenburger R, Inthal A, Bauer E, Krapf G, Kaindl U, Kauer M, Dworzak MN, **Stoiber D**, Haas OA & Panzer-Grümayer R. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. *Leukemia*. 2012; 26:927-33. **[Impact Factor: 9.6]**
- OA-16** Schneckenleithner C, Bago-Horvath Z, Dolznig H, Neugebauer N, Kollmann K, Kolbe T, Decker T, Kerjaschki D, Wagner KU, Müller M, **Stoiber D**, Sexl V. Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. *Oncotarget*. 2011;2:1043-54. **[Impact Factor: 4.8]**
- OA-15** Schuster C, Berger A, Hoelzl MA, Putz EM, Frenzel A, Simma O, Moritz N, Hoelbl A, Kovacic B, Freissmuth M, Müller M, Villunger A, Müllauer L, Schmatz AI, Streubel B, Porpaczy E, Jäger U, **Stoiber D***, Sexl V*. The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas. *Blood*. 2011;118:4635-45. **[Impact Factor: 9.9] * Equally contributed**
- OA-14** Eckelhart E, Warsch W, Zebedin E, Simma O, **Stoiber D**, Kolbe T, Rüllicke T, Mueller M, Casanova E, Sexl V. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK cell survival and development. *Blood*. 2011;117:1565-73. **[Impact Factor: 9.9]**
- OA-13** Pilz A, Kratky W, Stockinger S, Simma O, Kalinke U, Lingnau K, von Gabain A, **Stoiber D**, Sexl V, Kolbe T, Rüllicke T, Müller M, Decker T. Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. *J Immunol*. 2009;183:2286-93. **[Impact Factor: 5.8]**
- OA-12** Simma O, Zebedin E, Neugebauer N, Schellack C, Pilz A, Chang-Rodriguez S, Lingnau K, Weisz E, Putz EM, Pickl WF, Felzmann T, Müller M, Decker T, Sexl V,

- Stoiber D.** Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. *Cancer Res.* 2009;69:203-11. [**Impact Factor: 7.9**]
- OA-11** Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, Warsch W, Eckelhart E, **Stoiber D**, Weisz E, Schmid JA, Pickl WF, Baumgartner C, Valent P, Piekorz RP, Freissmuth M, Sexl V. Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. *Blood.* 2008;112:4655-64. [**Impact Factor: 9.9**]
- OA-10** Kovacic B, **Stoiber D**, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, Sexl V. STAT1 acts as a tumor promoter for leukemia development. *Cancer Cell.* 2006;10:77-87. [**Impact Factor: 26.6**]
- OA-09** **Stoiber D**, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, Weisz E, Artwohl M, Kleine OC, Muller M, Baumgartner-Parzer S, Ghysdael J, Freissmuth M, Sexl V. TYK2 is a key regulator of the surveillance of B lymphoid tumors. *J Clin Invest.* 2004;114:1650-8. [**Impact Factor: 13.1**]
- OA-08** Takaoka A, Hayakawa S, Yanai H, **Stoiber D**, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. *Nature.* 2003;424:516-23. [**Impact Factor: 36.3**]
- OA-07** Sexl V, Kovacic B, Piekorz R, Moriggl R, **Stoiber D**, Hoffmeyer A, Liebming R, Kudlacek O, Weisz E, Rothhammer K, Ihle JN. Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. *Blood.* 2003;101:4937-43. [**Impact Factor: 9.9**]
- OA-06** Stockinger S, Materna T, **Stoiber D**, Bayr L, Steinborn R, Kolbe T, Unger H, Chakraborty T, Levy DE, Müller M, Decker T. Production of type I IFN sensitizes macrophages to cell death induced by *Listeria monocytogenes*. *J Immunol.* 2002;169:6522-9. [**Impact Factor: 5.8**]
- OA-05** **Stoiber D**, Stockinger S, Steinlein P, Kovarik J, Decker T. *Listeria monocytogenes* modulates macrophage cytokine responses through STAT serine phosphorylation and the induction of suppressor of cytokine signaling 3. *J Immunol.* 2001;166:466-72. [**Impact Factor: 5.8**]
- OA-04** Kovarik P, **Stoiber D**, Evers PA, Menghini R, Neining A, Gaestel M, Cohen P, Decker T. Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway. *Proc Natl Acad Sci U S A.* 1999;96:13956-61. [**Impact Factor: 9.7**]
- OA-03** **Stoiber D**, Kovarik P, Cohny S, Johnston JA, Steinlein P, Decker T. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. *J Immunol.* 1999;163:2640-7. [**Impact Factor: 5.8**]
- OA-02** Kovarik P, **Stoiber D**, Novy M, Decker T. Stat1 combines signals derived from IFN-gamma and LPS receptors during macrophage activation. *EMBO J.* 1998;17:3660-8. Erratum in: *EMBO J* 1998;17:4210. [**Impact Factor: 9.2**]
- OA-01** Meinke A, Barahmand-Pour F, Wöhrl S, **Stoiber D**, Decker T. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. *Mol Cell Biol.* 1996;16:6937-44. [**Impact Factor: 5.5**]

Commentary

- C-1** Schuster C, Müller M, Freissmuth M, Sexl V, **Stoiber D**. Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells". *Biochem Biophys Res Commun*. 2008;366:869-70. [**Impact Factor: 2.5**]

Review Article

- RA-1** Strobl B, **Stoiber D**, Sexl V, Mueller M. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. *Front Biosci*. 2011;16:3214-32. [**Impact Factor: 3.5**] Review